Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Report From RSNA: Interest Expands In Breast Imaging Market

Executive Summary

Several new modalities are poised to change the way breast cancer screenings and diagnostics are performed as physicians and patients continue to search for technologies that can do more than standard X-rays. Ultrasound, computed tomography, and 3-D imaging are being touted as ways to improve the detection of tumors – especially in women with dense breast tissue – as well as to reduce exposure to radiation. Currently, the market is dominated by large, established manufacturers, but some new players are bringing in innovative options that are poised to push the field forward.

You may also be interested in...



GE Healthcare’s Invenia: Improving Breast Cancer Detection In Dense Breasts

GE Healthcare launched in June the Invenia Automated Breast Ultrasound System (ABUS), the first FDA-approved breast cancer screening option for women with dense breasts.

The Evolving World Of Breast Cancer Management

The device industry is playing a pivotal role in the evolution toward a more personalized approach to breast cancer management, with ongoing advances in minimally invasive treatment systems, tumor characterization and breast imaging technologies adding to the momentum. In the years ahead, as the breast cancer toolbox expands, the watchword will be “choice,” with physicians and patients offered more treatment options, targeted to their specific needs and desires, than ever before.

Start-Up News

Noteworthy news from medtech start-ups. This month we profile Ibris, which is developing prognostics to identify breast cancer patients in need of chemotherapy, and Delphinus Medical Technologies, whose platform enables 3-D full breast ultrasound.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

MT035569

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel